GLPG
$82.60
Galapagos NV
($2.54)
(2.98%)
GLPG
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($1.43)
Revenue:  $109.72 Mil
Friday
Mar 26
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, November 5, 2020

What do you expect when GLPG reports earnings?
Beat
Meet
Miss

Where is GLPG's stock price going from here?
Up
Flat
Down
Stock chart of GLPG
Analysts
Summary of analysts' recommendations for GLPG
Score
Grade
Pivots
Resistance
$85.67
$84.57
$83.58

$82.48

Support
$81.49
$80.39
$79.40
Tweet
Growth
Description
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.